Arylcyclohexylamines

Ketamine One Signs Definitive Agreement to Acquire Integrated Rehab and Performance Ltd.

Retrieved on: 
Thursday, June 3, 2021
Psychoactive drugs, Drugs, Neurochemistry, NMDA receptor antagonists, Antidepressants, Arylcyclohexylamines, Nicotinic antagonists, General anesthetics, Ketamine, Clinic

Pursuant to the terms of the Agreement and subject to the closing of the Transaction, IRPs Founder and Chief Executive Officer (CEO), Steven Inglefield, has agreed to become a director of Ketamine One.

Key Points: 
  • Pursuant to the terms of the Agreement and subject to the closing of the Transaction, IRPs Founder and Chief Executive Officer (CEO), Steven Inglefield, has agreed to become a director of Ketamine One.
  • The IRP team is excited to join Ketamine One and combine resources to grow its clinics across Canada.
  • Currently, Ketamine One has a network of 15 clinics across North America, with plans to further consolidate the highly fragmented industry.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

Ketamine (CAS 6740-88-1) Global Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 3, 2021
Health, General Health, Psychoactive drugs, Drugs, Neurochemistry, Arylcyclohexylamines, Ketones, Dissociative drugs, NMDA receptor antagonists, Nicotinic antagonists, Ketamine

The "Ketamine (CAS 6740-88-1) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ketamine (CAS 6740-88-1) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Ketamine.
  • The fifth chapter deals with Ketamine market trends and forecast, distinguish Ketamine manufacturers and suppliers.
  • The Ketamine global market report key points:

Myconic Capital Becomes Ketamine One

Retrieved on: 
Tuesday, June 1, 2021
Psychoactive drugs, Drugs, Neurochemistry, General anesthetics, Arylcyclohexylamines, Dissociative drugs, Nicotinic antagonists, Sedatives, Ketamine

VANCOUVER, British Columbia, June 01, 2021 (GLOBE NEWSWIRE) -- Myconic Capital Corp. (NEO: MEDI) is pleased to announce that effective June 3, 2021 it will change its name to KetamineOne Capital Limited (Ketamine One or the Company) from Myconic Capital Corp. and do business under the Ketamine One brand (the Name Change).

Key Points: 
  • VANCOUVER, British Columbia, June 01, 2021 (GLOBE NEWSWIRE) -- Myconic Capital Corp. (NEO: MEDI) is pleased to announce that effective June 3, 2021 it will change its name to KetamineOne Capital Limited (Ketamine One or the Company) from Myconic Capital Corp. and do business under the Ketamine One brand (the Name Change).
  • Ketamine Ones board of directors has appointed Dr. Mark Kimmins as the Companys Chief Medical Officer.
  • We are excited to reveal the re-brand of the Company to Ketamine One, which more accurately reflects our vision to quickly become a leader in the delivery of breakthrough mental wellbeing treatments, said Adam Deffett, VP of Capital Markets for Ketamine One.
  • KetamineOne Capital Limited (formerly Myconic Capital Corp.) (NEO: MEDI) is a single-purpose company focused becoming a North American leader in mental health.

Braxia Scientific Appoints Dr. David Greenberg to Board of Directors

Retrieved on: 
Monday, May 31, 2021
Mind, Drugs, Psychoactive drugs, Abnormal psychology, Psychiatric diagnosis, Arylcyclohexylamines, Ketamine, Sedatives, Depression, Mental disorder

TORONTO, May 31, 2021 /PRNewswire/ - Braxia Scientific Corp. (the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a research driven clinical platform developing and providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce it has appointed Dr. David Greenberg to its Board of Directors.

Key Points: 
  • TORONTO, May 31, 2021 /PRNewswire/ - Braxia Scientific Corp. (the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a research driven clinical platform developing and providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce it has appointed Dr. David Greenberg to its Board of Directors.
  • Dr. Greenberg consults for various companies on Sales, Marketing, Communications, and Business Development strategies.
  • Dr. Greenberg developed a national reputation for effectively conveying highly complex issues and concepts in a straightforward and entertaining manner.
  • Braxia Scientific is a research driven medical solutions company that aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others.

NeonMind Announces Creation of Medical Clinics Advisory Board to Guide Planning and Operation of Company-Branded Clinics Across Canada

Retrieved on: 
Wednesday, May 26, 2021
Psychoactive drugs, Drugs, Health, Arylcyclohexylamines, Dissociative drugs, Ketones, Nicotinic antagonists, Sedatives, Esketamine, Clinic, Ketamine, Mental health

Members of the advisory board will be comprised of experts on provincial and local health care access and advocacy, ketamine treatment and psychotherapy protocols, and clinical operations, strategy, and growth.

Key Points: 
  • Members of the advisory board will be comprised of experts on provincial and local health care access and advocacy, ketamine treatment and psychotherapy protocols, and clinical operations, strategy, and growth.
  • To view an enhanced version of this image, please visit:
    "The formation of our Medical Clinic Advisory Board is a critical next step in the creation of our clinics and treatment models.
  • Currently, ketamine and esketamine may legally be prescribed and administered in Canadian medical clinics, however there is a need for these clinics and treatments to be tailored to community and local health needs.
  • NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs.

/R E P E A T -- Braxia Scientific Introduces the Braxia Institute, Turning Research to Clinical Action; Over 200 Physicians and Health Care Providers to Attend Braxia's Symposium on Rapid Acting Anti-Depressants/

Retrieved on: 
Thursday, May 20, 2021
Psychoactive drugs, Drugs, General anesthetics, NMDA receptor antagonists, Arylcyclohexylamines, Nicotinic antagonists, Sedatives, Ketamine, Esketamine, Mental disorder

"With Braxia Scientific\'s knowledge base, we have a tremendous opportunity to radically improve the quality of care patients receive.

Key Points: 
  • "With Braxia Scientific\'s knowledge base, we have a tremendous opportunity to radically improve the quality of care patients receive.
  • Braxia Scientific will play a vital role in translating and implementing the latest research for psychedelic, ketamine and esketamine therapies for persons with depression and related disorders.
  • Braxia Scientific is primarily focused on (i) owning and operating multidisciplinary clinics providing treatment for mental health disorders and (ii) research activities related to discovering and commercializing novel drugs and delivery methods.
  • These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.

Accomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher’s Ketamine Programs

Retrieved on: 
Thursday, May 20, 2021
Psychoactive drugs, Drugs, NMDA receptor antagonists, Antidepressants, Arylcyclohexylamines, Nicotinic antagonists, Sedatives, Esketamine, Ketamine, Amyotrophic lateral sclerosis

as a scientific and clinical advisor for PharmaTher\xe2\x80\x99s clinical research programs involving ketamine as a potential treatment for major depressive disorders and amyotrophic lateral sclerosis (\xe2\x80\x9cALS\xe2\x80\x9d or \xe2\x80\x9cLou Gehrig\xe2\x80\x99s Disease\xe2\x80\x9d).\nMatthew Macaluso, D.O.

Key Points: 
  • as a scientific and clinical advisor for PharmaTher\xe2\x80\x99s clinical research programs involving ketamine as a potential treatment for major depressive disorders and amyotrophic lateral sclerosis (\xe2\x80\x9cALS\xe2\x80\x9d or \xe2\x80\x9cLou Gehrig\xe2\x80\x99s Disease\xe2\x80\x9d).\nMatthew Macaluso, D.O.
  • Professor Macaluso is also the Clinical Director of the UAB Depression and Suicide Center.
  • Matt has extensive experience in conducting clinical studies involving depression, including being a principal investigator of clinical studies involving esketamine which led to an FDA approval.
  • He is also a co-inventor for the novel use of ketamine as a potential treatment for ALS.

Update for Patient Access Solutions Opening and Managing New Center in Long Island, N.Y.

Retrieved on: 
Thursday, May 20, 2021
Psychoactive drugs, Health sciences, Drugs, Arylcyclohexylamines, Ketones, Muscarinic antagonists, Nicotinic antagonists, Sedatives, Therapy, Ketamine, Mental health

In addition to strategic relations efforts, PASO is aggressively moving forward into the exciting new area of Biological Mental health solutions.

Key Points: 
  • In addition to strategic relations efforts, PASO is aggressively moving forward into the exciting new area of Biological Mental health solutions.
  • To add value and experience to our Ketamine Therapy product offering, PASO has engaged in ongoing discussions with one of the country\xe2\x80\x99s leading Ketamine Therapy Clinic Companies.
  • A psychiatrist referral is also required.\nAfter an initial consultation, patients will be set up into a 6-9 session program.
  • This information is qualified in its entirety by cautionary statements and risk factors disclosure contained in certain of Patient Access Solutions Inc. Securities and Exchange Commission filings available at http://www.sec.gov .\n'

Braxia Scientific Introduces the Braxia Institute, Turning Research to Clinical Action; Over 200 Physicians and Health Care Providers to Attend Braxia's Symposium on Rapid Acting Anti-Depressants

Retrieved on: 
Thursday, May 20, 2021
Psychoactive drugs, Drugs, General anesthetics, NMDA receptor antagonists, Arylcyclohexylamines, Nicotinic antagonists, Sedatives, Ketamine, Esketamine, Mental disorder

"With Braxia Scientific\'s knowledge base, we have a tremendous opportunity to radically improve the quality of care patients receive.

Key Points: 
  • "With Braxia Scientific\'s knowledge base, we have a tremendous opportunity to radically improve the quality of care patients receive.
  • Braxia Scientific will play a vital role in translating and implementing the latest research for psychedelic, ketamine and esketamine therapies for persons with depression and related disorders.
  • Braxia Scientific is primarily focused on (i) owning and operating multidisciplinary clinics providing treatment for mental health disorders and (ii) research activities related to discovering and commercializing novel drugs and delivery methods.
  • These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.

Ehave KetaDASH Subsidiary Commences Data Collection for Potential Patients and Partnering Clinics

Retrieved on: 
Thursday, May 20, 2021
Psychoactive drugs, Drugs, Health sciences, Antidepressants, Arylcyclohexylamines, Ketones, Nicotinic antagonists, Sedatives, Ketamine, Therapy, Healthcare industry

b'MIAMI, May 20, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the \xe2\x80\x9cCompany\xe2\x80\x9d), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today its KetaDASH subsidiary has commenced data collection for potential patients and partnering clinics.

Key Points: 
  • b'MIAMI, May 20, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the \xe2\x80\x9cCompany\xe2\x80\x9d), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today its KetaDASH subsidiary has commenced data collection for potential patients and partnering clinics.
  • KetaDASH is available to ketamine clinics and qualified patients whose healthcare provider has prescribed it as a treatment.
  • The KetaDASH platform utilizes proprietary software developed by Ehave which allows patients and medical professionals to view detailed reports on the ketamine therapy\xe2\x80\x99s progress.
  • More information on KetaDASH is available at www.ketadash.com .\nKetamine therapy has turned out to be a life-changing alternative to antidepressants for many patients.